Entrectinib

Entrectinib is a tyrosine kinase inhibitor used as an anti-cancer medication. It targets specific proteins within cancer cells to inhibit their growth and spread.

Indications

-Treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. -Treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive.

Dosage

-Adults: 600 mg orally once daily with or without food. -Pediatric Patients: Dosage based on body surface area (BSA), typically 300 mg/m² once daily.

Contra-Indications

-Known hypersensitivity to entrectinib or any of its components. -Patients with severe hepatic impairment.

Special Precautions

-Monitor for signs of heart failure. -Regular liver function tests. -Monitor for central nervous system effects such as dizziness and cognitive changes. -Not recommended for use during pregnancy or breastfeeding without medical advice.

Side Effects

-Fatigue -Constipation -Dysgeusia (altered taste) -Edema -Dizziness -Anemia -Increased liver enzymes -Weight gain

Drug Interactions

-Strong CYP3A inhibitors or inducers may affect entrectinib levels. -Concurrent use with medications that prolong QT interval should be monitored closely.